Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: LTK007 who wrote (1583)	2/12/1999 1:23:00 AM
From: Pluvia	Read Replies (1) \| Respond to of 2135

<<but the NCI issue is of major importance EVEN IF it it is totally non-profitable--if through government funding they can make enough to make enough of this non-profitable treatment they might even save you if ever you were being consumed by incurable terminal cancer---would you say no thanks get out of here,cure me with something profitable you idealistic do-gooder creeps or not at all.>> Max, Stay away from that crack pipe - yer gett'n a little crazy here... If the drug is so unstable it can't economically be used for treatment nobody will get saved by it and it won't be available. End of story. Don't make the story more complicated than it is. BMY threw in the towel and dumped ENMD's drugs because they thought they were wasting time trying to develop them. Do you know more than BMY? dljdirect.com ************************ (BMY offical talking about ENMD's drugs) But such drugs require time and painstaking effort to develop, and many never make it to human, or clinical, trials. Kramer, (Bristol-Myers), said in the end, the drug was too tricky to produce. "It's not so much ability to make it. We can make buckets full of protein," Kramer said. But the drug, based on a naturally produced human protein, is not consistent enough to test in people, Kramer said. Bristol-Myers was using genetically engineered mammal cells grown in culture to produce the protein. EntreMed was taking a different route, using genetically engineered yeast to grow it. Both are time-honored methods used in drug production. Kramer said the yeast method does not meet Bristol-Myers'standards. ************************* There are many, many cancer treatments that have much more promise than this one. Go find a better cancer drug to get drippy about, you're wasting your effort here. But don't rely on my say so - ask Bristol Myers. Cheers Steve